Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Dr O’Malley discusses strategies in collaborating with multidisciplinary teams for quality of life, fertility preservation, and management of treatment related side effects to optimize patient wellbeing.
Integrating complementary and alternative therapies, psychological support, and nutrition into cancer care can enhance overall patient well being and create opportunities for holistic cancer care centers.Wilmington, Delaware, United States, Nov. 02, 2023 (GLOBE NEWSWIRE) Transparency Market Research Inc. - The global ovarian cancer treatment market was estimated to have acquired US$ 5.1 billion in 2022. It is anticipated to register a 15.4% CAGR from 2023 to 2031 and by 2031, the market is li